Immediate transient thrombocytopenia at the time of alemtuzumab infusion in multiple sclerosis Academic Article uri icon

Overview

MeSH Major

  • Anti-Inflammatory Agents
  • Methylprednisolone
  • Multiple Sclerosis, Relapsing-Remitting
  • Prednisone
  • Recovery of Function

abstract

  • In total, 3 of 22 paitents developed mild self-limited bruising associated with a drop in platelet count from their baseline during the intial 5-day course of alemtuzumab. Upon chart review, all 22 patients who received alemtuzumab developed an immediate mostly asymptomatic drop in platelet count which returned to normal within 2‚ÄČmonths post-infusion.

publication date

  • April 2018

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1177/1352458517699876

PubMed ID

  • 28287030

Additional Document Info

start page

  • 540

end page

  • 542

volume

  • 24

number

  • 4